Regeneron Shares Fall as Eylea Disappoints Investors

Regeneron Pharmaceuticals Inc., the drugmaker today celebrating the 25th anniversary of its incorporation, fell the most in five weeks after reporting sales for its eye drug Eylea that disappointed investors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.